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Climate change and an increased prevalence of gestational diabetes
Climate change, with a gradual warming of the environment, has 
been proposed for several decades, and there are increasing sci-
entific observations to support this. The potential reality has been 
very marked in Australia over recent years with a severe drought 
and then catastrophic bushfires. Climate change will have diverse 
effects on health, and one way may be the change in prevalence 
and clinical nature of different disorders.
The first observation that the prevalence of gestational di-
abetes mellitus (GDM) might vary with ambient temperature 
appeared more than a quarter of a century ago.1 Subsequent 
work in Australia, using the previous Australasian Diabetes in 
Pregnancy Society (ADIPS) criteria, found a non-significant change 
in the fasting glucose level but a significant increase in the two-
hour glucose level in the warmer weather. Overall, there was no 
change in prevalence.2 A follow-on climate chamber study found a 
significant increase in the post-glucose load levels with increasing 
temperatures from 25 to 30°C.3 This was related to increased ar-
terialisation of the peripheral blood with increasing temperatures.
In 2016, another Australian study, using the current ADIPS 
criteria, found a marked increase in the prevalence of GDM in 
the summer compared with the winter seasons.4 These obser-
vations have subsequently been found, reported, and confirmed 
in many parts of the world5–7 although there have been some 
negative outcomes.8 Many of these studies relate to the increas-
ing prevalence of GDM in the summer months with climate 
change, although to our knowledge, this aspect has not been 
specifically examined.
What has not been systematically examined is whether these 
changes are acute and related to the temperature of the day, the 
temperature of the pathology collection centre, or whether it is a 
seasonal factor, perhaps related to the accumulation of brown fat 
and changes in insulin sensitivity.5
What is known is that the overall prevalence of GDM in most 
reported studies is higher in summer than in winter – or in hot-
ter rather than colder environs. In Australia, the change in the 
diagnostic criteria for GDM has resulted in an approximate 50% 
increase in prevalence9 and the changed criteria appears to be 
exacerbating the seasonal variation. Whether the increased and 
increasing prevalence of GDM occasioned by both these factors 
is an advantage to the outcome of the pregnancy remains to be 
determined. In Australia, perhaps standardisation of the tempera-
ture in pathology collection areas could be considered. Or per-
haps criteria adjustment may be required for different seasons.
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Gestational diabetes mellitus screening in pandemic times: Are there viable  
alternatives?
The COVID-19 outbreak has changed medical care guidelines 
across all medical specialties. Various patients are in vulnerable 
situations where postponing care is not an option, such as the 
case for pregnant women. Efforts are being made to maintain the 
quality of care during pregnancy while simultaneously reducing 
exposure to COVID-19.
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Recently, Canadian1 and UK2 Societies of Obstetrics and 
Gynaecologists alongside Queensland Health3 proposed alter-
natives to the screening of gestational diabetes mellitus (GDM) 
during the COVID-19 pandemic. In short, the alternative rec-
ommendation for GDM screening during pregnancy involves 
demographic characteristics combined with haemoglobin A1c 
(HbA1c) or non-fasting random plasma glucose for all preg-
nant women without pre-existing diabetes. However, while 
HbA1c above the 5.7% threshold is related to high specific-
ity, it has low diagnostic sensitivity of approximately 25% as a 
GDM predictor.1
The ultrasound measurement of maternal visceral adipose tis-
sue (m-VAT) has been shown as a useful indicator of GDM among 
pregnant women, emerging as a marker of metabolic risk with 
greater accuracy than pre-pregnancy body mass index (BMI) com-
patible with obesity that reaches maximum sensitivity ranging 
from 20%4 to 56%.5 m-VAT can also be easily implemented during 
a routine ultrasound with no additional cost and fast learning 
curve among sonologists and sonographers. The probe is placed 
in a sagittal position 2 cm above the maternal umbilical scar and 
the electronic caliper placed from the aortic anterior wall to the 
linea alba. However, despite the aforementioned benefits, there 
is no established consensus regarding the cut-off for this test. 
Different m-VAT thresholds were found to be associated with in-
creased GDM risk, ranging from 42.74 to 48 mm,6 when controlling 
for maternal age, pre-pregnancy BMI and related to GDM diagnos-
tic criteria proposed by the International Association of Diabetes 
and Pregnancy Study Groups (IADPSG). External validity of the 
findings is suggested by adjusting for ethnicity, maternal age and 
educational level confounders in previous regression analyses 
with similar results.4,6 The m-VAT sensitivity, a critical assessment 
of a diagnostic test, when using a 42.7 mm threshold resulted in 
an impressive performance of 87% (95% CI 60–98%), with a spec-
ificity of 62%.4
Our group recently demonstrated that a 45 mm m-VAT thresh-
old for early pregnancy screening among a low-risk outpatient preg-
nant sample showed significant crude and adjusted odds ratios of 
13.4 (95% CI 2.9–61.1) and 8.9 (95% CI 1.9–42.2), respectively.5 A 
similar result was obtained among pre-gravid non-obese women 
(BMI < 25.0), with crude and adjusted odds ratios of 16.6 (95% CI 
1.9–142.6) and 14.4 (95% CI 1.7–125.7), respectively. In pre-gravid 
obese women (BMI > 30), the use of a 45 mm m-VAT threshold was 
not significantly able to predict GDM risk. The final accuracy of the 
45 mm m-VAT threshold showed a 66% ability to predict GDM in the 
whole sample. Not only so, but the predictive ability of the thresh-
old increased to 72% among non-obese pre-gravid women only. 5
We believe that the inclusion of m-VAT during routine early ul-
trasound can identify patients who would benefit from additional 
investigations regarding GDM, as well as identify patients who do 
not require unnecessary laboratory tests, which can risk exposure 
to COVID-19. As this procedure can be done in the first 20 weeks 
of pregnancy, a nuchal translucency evaluation could be used as a 
form of risk stratification for GDM.






José Antônio de Azevedo Magalhães7,1
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
2Department of Nutrition, Hospital de Clínicas de Porto Alegre, Porto 
Alegre, Brazil
3School of Medicine, Universidade Federal do Rio Grande do Sul, 
Porto Alegre, Brazil
4Department of Social and Behavioral Health Sciences, Dalla Lana 
School of Public Health, University of Toronto, Toronto, Canada
5Maternal-fetal Division (Head), Ottawa General Hospital, 
Ottawa, Canada
6School of Medicine, University of Ottawa, Ottawa, Canada
7Maternal-Fetal Division (Head), Hospital de Clínicas de Porto Alegre, 




 1. Yamamoto JM, Donovan LE, Feig DS, Berger H. Urgent Update – 
Temporary Alternative Screening Strategy for Gestational Diabetes 
Screening during the COVID-19 Pandemic, 2020. Available from 
URl: https://www.sogc.org/en/conte nt/featu red-news/Gesta tiona l- 
Diabe tes-Scree ning-Durin g-COVID -19-Pande mic.aspx
 2. RCOG. Royal College of Obstetricians and Gynaecologists. Coronavirus 
(COVID-19) Infection in Pregnancy. Version 7 - Information for 
healthcare professionals. 2020: 1–54.
 3. Guidelines QH. Queensland Clinical Guideline. Gestational Diabetes 
Mellitus. 2020; Available from URL: https://www.health.qld.gov. 
au/__data/asset s/pdf_file/0024/95050 5/f-gdm-diagn osis-covid.
pdf
 4. Thaware PK, Patterson CC, Young IS, Casey C, McCance DR. 
Clinical utility of ultrasonography-measured visceral adipose 
tissue depth as a tool in early pregnancy screening for gesta-
tional diabetes: a proof-of-concept study. Diabetic Med 2019; 
36(7): 898–901.
 5. Rocha AS, Bernardi JR, Matos S, Kretzer DC, Schöffel AC, Goldani 
MZ, de Azevedo Magalhães JA. Maternal visceral adipose tis-
sue during the first half of pregnancy predicts gestational di-
abetes at the time of delivery - a cohort study. PloS ONE 2020; 
15(4): e0232155.
 6. De Souza LR, Berger H, Retnakaran R, Maguire JL, Nathens AB, 
Connelly PW, Ray JG. First-trimester maternal abdominal adipos-
ity predicts dysglycemia and gestational diabetes mellitus in mid-
pregnancy. Diabetes Care. 2016; 39: 61–64.
